Anzeige
Mehr »
Login
Samstag, 18.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Letzte Chance, bevor die Bohrer dieses "Monster"-Vorkommen bei einem 13-Millionen-Unternehmen ansteuern
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DN2N | ISIN: SE0009663826 | Ticker-Symbol: 6MA
Frankfurt
17.01.25
09:16 Uhr
8,160 Euro
+0,085
+1,05 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
AMBEA AB Chart 1 Jahr
5-Tage-Chart
AMBEA AB 5-Tage-Chart
RealtimeGeldBriefZeit
8,1408,38513:04
GlobeNewswire (Europe)
316 Leser
Artikel bewerten:
(1)

Ambea AB: Year-end report 2023

Finanznachrichten News

Clear earnings improvement creating future opportunities.

CEO comment:
We ended the year on a strong note and our large divisions, Vardaga, Nytida and Stendi, posted favourable earnings for the fourth quarter. The strong trend for Stendi continued and the division's occupancy surpassed our expectations, which had a positive impact on earnings. Stendi's EBITA increased to SEK 70 million (SEK 24 million). Vardaga's earnings strengthened, driven by increased occupancy and operational improvements. During the period, Nytida opened two new residential facilities under own management with a total of 15 places.

The fact that we delivered a strong financial performance while also receiving high ratings in the quarter's care receiver surveys is particularly gratifying. In the National Board of Health and Welfare's Unit Survey, both Vardaga and Nytida scored well above the average for both private and public providers. We are also proud that our employer brand has been strengthened by more of our employees being likely to recommend Ambea as an employer to a friend or acquaintance.

Organic growth and margin improvement
In the fourth quarter, net sales rose 6 per cent to SEK 3,412 million (3,225). Organic growth was 7 per cent. EBITA increased to SEK 286 million (170), corresponding to a margin of 8.4 per cent (5.3).

Share buyback
Free cash flow totalled SEK 592 million (402). Due to the company's strong financial position and reduced indebtedness, the Board decided to implement a share buyback. The programme comprises a maximum of 3 million shares. The conditions surrounding the buyback have been communicated separately. The dividend proposal for 2024 is SEK 1.50 per share (SEK 1.25 in 2023), in line with the Group's dividend policy.

Fourth quarter October-December

  • Net sales rose 6 per cent to SEK 3,412 million (3,225).Organic growth was 7 per cent and acquired/divested growth was -1 per cent.
  • Operating profit (EBIT) totalled SEK 264 million (140).
  • EBITA was SEK 286 million (170), representing a margin of 8.4 per cent (5.3).
  • Profit for the period totalled SEK 133 million (22).
  • Earnings per share were SEK 1.48 (0.24) before and after dilution.
  • Cash conversion was 125.7 per cent (121.3).
  • Free cash flow totalled SEK 592 million (402).

Full-year January-December

  • Net sales rose 5 per cent to SEK 13,312 million (12,635).
    Organic growth was 6 per cent and acquired/divested growth was -1 per cent.
  • Operating profit (EBIT) totalled SEK 981 million (843).
  • EBITA was SEK 1,076 million (954), representing a margin of 8.1 per cent (7.6).
  • Profit for the period totalled SEK 455 million (366).
  • Earnings per share were SEK 5.07 (3.89) before and after dilution.
  • Cash conversion was 94.9 per cent (95.6).
  • Free cash flow totalled SEK 1,631 million (1,451).
  • The Board proposes a dividend of SEK 1.50 (1.25) per share for 2023

Webcast/telephone conference
In connection to the announcement, Ambea will host a telephone conference today at 10:00 (CET). The presentation will be held in English and available as webcast on www.ambea.com or direct link:
https://edge.media-server.com/mmc/p/72p94oom

Telephone conference
To participate the conference call, register before the call using the link below. Upon registration you will receive a dial-in number and a unique personal PIN code. To ensure that the connection to the conference call is working, please dial in ten minutes before the start time of the conference call.
Telephone conference registration:
https://register.vevent.com/register/BI503887ba91644da99b0188468b86d56b

The quarterly earnings report and associated presentation will be available on www.ambea.com

This disclosure contains information that Ambea is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014) and the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 08-02-2024 07:00 CET.

For more information, contact:

Susanne Vogt, head of IR
E-mail: ir@ambea.se

Ambea press contact
Telephone: +46 (0)10 33 00 501
E-mail: press@ambea.se

Ambea is Scandinavia's leading competence -based care company. Ambea has 31,000 employees who are creating a good life for every care receiver in our 950 units. We aim to be the quality leader in all that we do and our vision is to make the world a better place, one person at a time. Ambeas head office is located in Solna, Sweden. Ambea is listed on Nasdaq Stockholm.


© 2024 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.